October 9, 2026
Agency
Clinical Trial Insurance: What Medtech Startups Need Before IRB Approval
Your first human subjects study is the moment your risk profile changes. Your insurance program needs to change with it, before the protocol goes to review.
For most medtech startups, the path to a first-in-human study is a sequence of regulatory milestones. Insurance tends to surface late, usually when a site’s contracting office or a lead investor asks for a certificate. Discovering then that your coverage doesn’t respond to a clinical study can delay activation by weeks.
Here’s what to have sorted out before your submission goes in.
What Clinical Trial Liability Insurance Is, and Why It’s Distinct
Clinical trial liability insurance responds to bodily injury claims from study participants arising from the investigational device or the conduct of the study. It’s a different animal from the policies most startups already carry.
General liability covers premises and operations risk, such as a visitor slipping in your office. It isn’t designed around injury to a research subject from an unapproved device.
Product liability is written around marketed products. Some policies extend to clinical trials, and clinical trial coverage is often included as standard for companies with approved products on the market. But a pre-revenue startup with no commercial product frequently has no such policy at all, or has one that excludes investigational use.
Clinical trial coverage is sometimes folded into a product liability form and sometimes written standalone. Confirm in writing which you have, and whether it covers investigational devices.
IRB Requirements and Insurance Documentation: What Reviewers Look For
A note on precision: in the U.S., the IRB’s core job is protecting human subjects, not underwriting your coverage. Requirements for insurance documentation vary by institution, and many sites handle proof of coverage through the clinical trial agreement and contracting office rather than the IRB itself. Outside the U.S., many regulators and ethics committees do require insurance or indemnity to be in place before approval.
Where the IRB does engage with this topic is the informed consent document. For research involving more than minimal risk, federal regulations require the consent form to explain whether compensation and medical treatment are available if a participant is injured, and what they consist of. That language has to match reality. If the consent form promises coverage for research-related injury, your insurance and sponsor agreements need to back it up.
Common submission errors:
- Consent language promising injury compensation that no policy or agreement actually funds
- Certificates showing general liability only, with no clinical trial or investigational device coverage
- Policy territory or study-type exclusions that don’t match the protocol’s sites
- Coverage periods that end before the trial’s follow-up period does
- Certificates naming the startup but not the sites, investigators, or CRO as additional insureds where agreements require it
Investigator Coverage: Who Needs It and How It Interacts With Sponsor Liability
Investigators carry their own professional liability exposure for how they conduct the study: consent, protocol adherence, patient care. That coverage typically comes through their institution’s program or their own malpractice policy, and it generally covers their professional acts, not harm caused by a defective investigational device.
That distinction is why the sponsor’s role matters. Sponsors are generally expected to indemnify investigators and sites against loss arising from the study, and a CRO’s perspective is the same: adequate sponsor coverage is what contains losses from the study device that the CRO isn’t responsible for. In practice, your clinical trial policy should include additional insured or indemnity language extending protection to the CRO, sites, and investigators for claims arising from the investigational device.
If a physician is also the device developer and acts as sponsor-investigator, the two roles and their exposure merge, and that needs deliberate structuring.
The 5 Coverage Questions to Answer Before Your First Human Subjects Study
- Does my current policy cover investigational devices and human subjects, or does it exclude them?
- Do the limits and policy period fit the study, including the follow-up period after last enrollment?
- Does the territory cover every planned site, including any outside the U.S.?
- Who needs additional insured or indemnity protection under our site and CRO agreements, and is it written into the policy?
- Does our consent form’s injury-compensation language match what our insurance and agreements actually provide?
Structuring Coverage to Satisfy Both the IRB and Your Series A Investors
These audiences want overlapping things for different reasons. Sites and reviewers want assurance that injured participants have a funded path to care. Investors want assurance that one adverse event won’t consume the round.
A practical structure:
- Obtain dedicated clinical trial coverage before submission, not after approval, so certificates are ready when contracting asks.
- Align limits to the study’s size and risk class, and document the reasoning. Investors and counsel tend to respond well to a coverage rationale rather than a number picked to meet a minimum.
- Coordinate with regulatory counsel so contracts, consent language, and policy terms say the same thing.
The Bottom Line
A clinical study turns hypothetical product risk into real human exposure. The startups that move smoothly through IRB review, site activation, and a financing round are the ones whose insurance, consent language, and contracts were built to match before anyone asked.
This article is for educational purposes only and does not constitute legal, regulatory, or insurance advice. Requirements vary by institution, jurisdiction, and study design. Consult regulatory counsel and a licensed insurance professional with life sciences expertise.